(Q38713045)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Changhai Lei

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Wenyan Fu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Tian Li

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Qingning Yuan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Feifei Wang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Gaojian Lv

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Yuanyuan Lv

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Xiaoyan Fan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Yafeng Shen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Fangxing Lin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ying Tang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Xuting Ye

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Yongji Yang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

language of work or name

English

0 references

publication date

8 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

Cancer stem cells: current status and evolving complexities

5 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

DNA damage repair pathways in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Notch inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Alterations in Notch signaling in neoplastic lesions of the human cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

EGF receptor and Notch signaling act upstream of Eyeless/Pax6 to control eye specification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

More than markers: biological significance of cancer stem cell-defining molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Targeting notch signaling pathway in cancer: clinical development advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Analyzing real-time PCR data by the comparative C(T) method

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAG0339

10.1126/SCITRANSLMED.AAG0339

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28275151%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference